Advertisement

Click here for more guidelines.

 
 




CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 1996; 27:453-461
© 1996 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stambler, B.
Right arrow Articles by Ellenbogen, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stambler, B.
Right arrow Articles by Ellenbogen, K.

Pharmacologic alterations in human type I atrial flutter cycle length and monophasic action potential duration. Evidence of a fully excitable gap in the reentrant circuit

BS Stambler, MA Wood, and KA Ellenbogen

Department of Cardiology, West Roxbury Veterans Affairs Medical Center, Harvard Medical School, Massachusetts 02132, USA.

OBJECTIVES. This study compared the effect of changes in action potential duration versus conduction velocity on atrial flutter cycle length to determine whether there is a fully or partially excitable gap in atrial flutter. BACKGROUND. In an excitable gap reentrant circuit, cycle length is proportional to conduction velocity. Action potential duration is not a direct determinant of cycle length when the gap is fully excitable. METHODS. Right atrial monophasic action potentials were recorded from 41 patients during type I atrial flutter before and during pharmacologic interventions. RESULTS. Adenosine (17 +/- 3 mg [mean +/- SD]) shortened (p < 0.001) action potential duration but did not change cycle length. Edrophonium (10 mg) had no significant effect on action potential duration or cycle length. Isoproterenol (0.03 microgram/kg body weight per min) shortened (p < 0.05) and procainamide (15 mg/kg, then 2 mg/min) prolonged (p < 0.001) action potential duration and cycle length. Alterations in cycle length were not correlated with changes in action potential duration. Procainamide's prolongation of action potential duration was reversed by adenosine without affecting cycle length. Procainamide's prolongation of action potential duration and cycle length was partially reversed by isoproterenol. Adenosine's and isoproterenol's shortening of action potential duration and isoproterenol's shortening of cycle length were enhanced by procainamide. CONCLUSIONS. Atrial flutter cycle length is determined primarily by conduction velocity and does not depend directly on action potential duration. Atrial flutter has a fully excitable gap, and procainamide does not convert the gap from full to partial excitability. Adenosine and isoproterenol interact with procainamide such that their effects are enhanced and procainamide's effects are diminished.


This article has been cited by other articles:


Home page
EuropaceHome page
M. Gulizia, S. Mangiameli, S. Orazi, G. Chiaranda, G. Boriani, G. Piccione, N. DiGiovanni, A. Colletti, C. Puntrello, G. Butera, et al.
Randomized comparison between Ramp and Burst+ atrial antitachycardia pacing therapies in patients suffering from sinus node disease and atrial fibrillation and implanted with a DDDRP device
Europace, July 1, 2006; 8(7): 465 - 473.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
F. Bode, M. Kilborn, P. Karasik, and M. R. Franz
The repolarization-excitability relationship in the human right atrium is unaffected by cycle length, recording site and prior arrhythmias
J. Am. Coll. Cardiol., March 1, 2001; 37(3): 920 - 925.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
M. R Franz
Current status of monophasic action potential recording: theories, measurements and interpretations
Cardiovasc Res, January 1, 1999; 41(1): 25 - 40.
[Full Text] [PDF]


Home page
CirculationHome page
B. S. Stambler, M. A. Wood, and K. A. Ellenbogen
Antiarrhythmic Actions of Intravenous Ibutilide Compared With Procainamide During Human Atrial Flutter and Fibrillation : Electrophysiological Determinants of Enhanced Conversion Efficacy
Circulation, December 16, 1997; 96(12): 4298 - 4306.
[Abstract] [Full Text]


Home page
CirculationHome page
F. X. Roithinger, M. R. Karch, P. R. Steiner, A. SippensGroenewegen, and M. D. Lesh
Relationship Between Atrial Fibrillation and Typical Atrial Flutter in Humans : Activation Sequence Changes During Spontaneous Conversion
Circulation, November 18, 1997; 96(10): 3484 - 3491.
[Abstract] [Full Text]


Home page
CirculationHome page
C.-T. Tai, S.-A. Chen, C.-E. Chiang, S.-H. Lee, K.-C. Ueng, Z.-C. Wen, J.-L. Huang, Y.-J. Chen, W.-C. Yu, A.-N. Feng, et al.
Characterization of Low Right Atrial Isthmus as the Slow Conduction Zone and Pharmacological Target in Typical Atrial Flutter
Circulation, October 21, 1997; 96(8): 2601 - 2611.
[Abstract] [Full Text]


Home page
CirculationHome page
B. S. Stambler and K. A. Ellenbogen
Elucidating the Mechanisms of Atrial Flutter Cycle Length Variability Using Power Spectral Analysis Techniques
Circulation, November 15, 1996; 94(10): 2515 - 2525.
[Abstract] [Full Text]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement